Comparison of adagrasib prices in various places: Is there any obvious difference?

Adagrasib (Adagrasib), as a type of oral small molecule covalent inhibitor, has emerged in the field of cancer treatment with its unique mechanism of action. It irreversibly and selectively binds to KRAS G12C, locking this oncogenic driver in an inactive guanosine diphosphate binding state, thereby effectively blocking its carcinogenic effect. Adagrasiib not only exhibits excellent pharmacodynamic properties, but also has a long half-life of 23 hours, dose-dependent pharmacokinetics and central nervous system penetration, which provide strong support for its broad prospects in clinical application.

Adagrasib has demonstrated significant clinical activity and good tolerability in the treatment of KRAS G12C mutant cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). As an oral tablet, it is easy to take and is usually recommended twice a day, regardless of eating or not, which greatly improves the convenience of medication for patients.

However, despite the breakthrough in efficacy of adagrasib, its accessibility in my country faces considerable challenges. Since the original product has not yet been launched in the Chinese market and has not been included in the medical insurance system, domestic patients currently mainly purchase this drug through overseas channels. In the international market, the original adagrasib is expensive, as high as hundreds of thousands of yuan, and the price is also affected by exchange rate changes, which undoubtedly brings a heavy financial burden to many patients.

Generic versions of adagrasib are already on the market. This generic drug developed by Lucius Pharmaceuticals in Laos is basically the same as the original product in terms of drug ingredients, but the price is much more affordable. Each box of 90 tablets of 200 mg generic medicines sells for about 4,000 yuan. Although the price is still affected by the exchange rate, its price advantage is quite significant compared with the original medicines, providing the possibility of treatment for more patients.